Dicot is developing a new potency drug with the aim to treat erectile dysfunction and premature ejaculation better than existing drugs. The company has previously announced that the clinical phase 1 trial with LIB-01 is planned to start in August.

Today, the company has submitted the application to the Swedish Medical Products Agency to start a phase 1 clinical trial. This study is a "first-in-human" trial, and it will be the first time that LIB-01 is tested in humans. The main objective with the trial is to evaluate the safety and tolerability of LIB-01 in humans.

"We are very happy that after several years of hard work we have now submitted all the documentation that justifies that we are ready to take LIB-01 into clinical trials," comments Elin Trampe, CEO at Dicot.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 739 80 14 08
E-mail: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit www.dicot.se.